Seoul Viosys Begins Mass Production of 25Gbps VCSELs for 5G Communication Applications
Seoul Viosys (KOSDAQ: 092190), a leading compound semiconductor provider, announced that for the first time in Korea, Seoul Viosys succeeded in developing vertical cavity surface emitting laser (VCSEL) technology, a near-field-only 25Gbps laser diode compatible with 5G wired networks for transmitting and receiving, and has started mass production to supply these products to three initial customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210128005444/en/
[Figure 1] Schematic diagram of 5G network application using Seoul Viosys’ VCSELs (Graphic: Business Wire)
VCSEL is a laser diode technology that converts electrical signals into optical signals. It has recently attracted attention as a light-based communication technology that achieves ultra-high-speed data communication in 5G environments. This technology is necessary for AR/VR, 3D sensing and the camera-applied ToF (Time of Flight) for smartphones, and automotive LiDAR. Seoul Viosys’ VCSELs for sensor applications have already received customers’ approval and will be mass-produced within the first quarter of 2021, and the LiDAR technology is also undergoing the approval process to be supplied to an automotive system solution provider. According to the Yole Développement, a leading compound semiconductor research firm, the global VCSEL market is expected to grow 18.4% annually from $1.1B in 2020 to $2.7B in 2025.
The 25Gbps VCSEL developed by Seoul Viosys is a high-performance laser diode technology that emits light vertically from semiconductor substrates to enable fast communication. Currently, the 25Gbps VCSEL market has seen three large U.S. companies – II-VI, Lumentum, and Broadcom – involved in a power struggle for these high value-added products, which have more than 10 times of selling price that of LED. Seoul Viosys’ VCSEL can be implemented in a single channel or four-channel configurations, depending on its intended use, and the four-channel implementation features 100Gbps (4x) of high-capacity and high-quality data reception and transmission. Although the VCSEL technology exhibits a high degree of difficulty in implementation, it is expected to cover a wide range of applications in the future, as it is price competitive compared to horizontal-type laser diodes that emit light from the sides.
“As the paradigm shift has progressed in the recent noncontact era, interest in VCSEL technology is growing, since it is a critical technology for implementing the Internet of Things (IoT) environment. Seoul Viosys will continue to research and develop the VCSEL technology to expand and apply our differentiated VCSELs to 5G communication-based smart cities, autonomous driving applications, AR/VR, and industrial IoT markets,” said an official at Seoul Viosys.
About Seoul Viosys
Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Micro Clean Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2019). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Micro Clean Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/.
Seoul Semiconductor Co., Ltd.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tanner Pharma Group Expands Ex-US Access Program to Provide LEUKINE® for Use in Patients with Respiratory Illness Associated with COVID-198.3.2021 18:53:00 EET | Press release
Tanner Pharma Group (Tanner) today announced expansion of the LEUKINE Access Program (LeAP) as a channel for distribution of LEUKINE® (sargramostim) in international markets. LEUKINE®, approved by the US FDA in 1991 and now manufactured by Partner Therapeutics (PTx), is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that stimulates the immune system and has been used in leukemia patients to reduce the risk of infection. PTx recently announced that a clinical trial of Leukine® conducted in Belgium of hospitalized COVID-19 patients suffering from acute hypoxic respiratory failure requiring supplemental oxygen met the primary endpoint of significant improvement in lung function. Improvement in oxygenation of at least 33% or more from baseline was seen in 54% of patients on the LEUKINE® plus standard-of-care (SOC) arm versus 26% of patients on SOC (p=.0147). Tanner provides a regulatory-compliant pathway to make LEUKINE® available in international markets. If a pat
H.I.G. Capital Expands European WhiteHorse Team with the Addition of Laurent Vaille and Charles Bourgeois8.3.2021 18:30:00 EET | Press release
H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with over €35 billion of equity capital under management, is pleased to announce the expansion of its European WhiteHorse team with the addition of Laurent Vaille and Charles Bourgeois as Principals. Laurent will be based in H.I.G.’s London office, and Charles is based in H.I.G.’s Paris office. Laurent has 13 years of experience in direct lending and corporate finance. He was previously an Executive Director in the Private Debt division of Tikehau Capital in Paris. Prior to that, he worked for Ernst & Young and Deloitte Finance. Charles has 13 years of experience in direct lending and corporate finance. Prior to joining H.I.G., he was an Executive Director in the Private Debt division of Tikehau Capital in Paris. He was previously with GE Capital in the leveraged finance division, after working at SG and LD&A Jupiter. Commenting on the hire, Pascal Meysson, Head of H.I.G. WhiteHorse Europe, said, “Hiring profe
PerkinElmer Adds HPLC Columns to Consumables Portfolio8.3.2021 18:22:00 EET | Press release
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it has added state-of-the-art columns and chemistries to its LC consumables portfolio by acquiring ES Industries, based in West Berlin, New Jersey in the U.S. ES Industries is known for its innovative and highly efficient HPLC and supercritical fluid chromatography (SFC) column chemistries. The team has over 40 years of experience delivering columns with superior reliability, scalability, and reproducibility that are used routinely for method development processes, LC/MS analysis, quality control and preparative purification. Building on PerkinElmer’s recently announced LC 300TM HPLC/UHPLC and SimplicityChromTM CDS solution, along with its world class reagents and OneSource® laboratory services, the addition of these column technologies brings customers, such as those in pharmaceuticals/biopharmaceuticals, chemicals, food safety and environmental industries, the convenience of a singl
Veristat Congratulates Origin Biosciences for FDA Approval of Nulibry During the Week of Rare Disease Day 20218.3.2021 17:25:00 EET | Press release
Veristat, a scientific-minded, global clinical research organization (CRO), today congratulated Origin Biosciences for their FDA approval of Nulibry (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. This rare disease product received FDA approval on Friday, 26 February 2021, during the week when the world celebrated #RareDiseaseDay2021. Veristat’s biostatisticians, programmers, and medical writers collaborated with Origin Biosciences to support the New Drug Application (NDA) for Nulibry. The entire Veristat team is honored to know that the hard work and perseverance of the combined Origin/Veristat team brought new hope for children whose lives are shortened by the devastating disease MoCD Type A. “We thank the entire Veristat team who worked diligently to help us bring this critical therapy to patients with no other FDA-approved treatment options,” said Dr. Liza Squires, Origin Chief Medical
CBS News “Global Thought Leaders” Series Features Echosens: Video Showcases FibroScan® as Medical Gold Standard8.3.2021 17:01:00 EET | Press release
Echosens, a high-technology company offering the FibroScan ® family of products, is pleased to announce that it has been chosen for the “Global Thought Leaders” series broadcast on CBS News. View a short video highlighting the Company’s groundbreaking work in the development of vital medical resources, including FibroScan ® , a noninvasive solution for measuring liver elasticity and fat content of the liver at the point of care. “We’re pleased to be selected by CBS News and proud of the video created at our international headquarters in Paris which captures the essence of Echosens, including interviews with some of our top leaders and a clinician performing a FibroScan ® exam with her patient,” says Dominique Legros, Group CEO, Echosens. “Reliable, accurate and affordable, FibroScan ® is designed to address a growing liver disease epidemic. Nonalcoholic fatty liver disease (NAFLD) affects approximately 25% of the worldwide population and as many as 6% are affected by NASH, which is exp
Infor and C3 AI Form Strategic Partnership to Deliver Scalable Enterprise AI Industry Applications8.3.2021 17:00:00 EET | Press release
C3 AI (NYSE: AI), a leading enterprise AI software provider, and Infor, an ERP technology cloud leader, today announced a wide-ranging strategic alliance designed to jointly expand enterprise-class artificial intelligence (AI) solutions across applicable industries to extend Infor’s native machine learning capabilities. This will allow Infor to explore expansion of its industry offerings into edge scenarios and analyze ways to provide deeper capabilities beyond standard Infor offerings. Infor plans to market, license, and deploy C3 AI prebuilt solutions to Infor customers under the Infor brand and to explore new solutions using the C3 AI® Suite. Infor and C3 AI expect to leverage both companies’ existing digital portfolios to collaborate on new integrated enterprise AI applications that can support specific industry needs. The initial focus will be on predictive maintenance surrounding Internet of Things (IoT) systems with the goal of providing a more proactive and accurate maintenance
NielsenIQ Establishes Independence as a Standalone Company8.3.2021 17:00:00 EET | Press release
Today, NielsenIQ begins its next chapter as an independent company with the closing of its acquisition by Advent International in partnership with incoming Executive Chairman and CEO James “Jim” Peck. As a standalone business, NielsenIQ is better positioned to accelerate its transformation and strengthen its market-leading position. To move forward as a definitive leader in the FMCG industry and usher in a new era of technological advancements and innovation, three new leaders will join NielsenIQ. Mohit Kapoor joins as Chief Technology Officer, overseeing all aspects of technology. Steve Matthesen, a Nielsen veteran, joins as Chief Strategy Officer to help develop and execute the corporate strategy and other key initiatives. Curt Miller joins as Chief Transformation Officer to drive organizational alignment that supports NielsenIQ’s growth strategy. “NielsenIQ has a unique opportunity to become a nimble partner with the flexibility to increase strategic investments and innovation in th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom